Hematology · Haemostasis

Heparin-Induced Thrombocytopenia: When the Blood Thinner Causes Clots

You gave heparin to PREVENT clots. A week later the platelet count has quietly halved and the patient's leg is swollen and clotted. Every instinct says "low platelets — they'll bleed, transfuse them." Every instinct is wrong. This is the diagnosis where the blood thinner is the culprit, the falling platelets threaten clotting not bleeding, and the cure is MORE anticoagulation with a different drug. Miss it and you lose a limb — or a life.

⏱ 12 min read🎯 Linked lesson: HIT· Updated 2026-07-16

THE SCENE

Day 3 after a hip replacement. Routine: a small prophylactic dose of heparin under the skin to keep clots away. The patient is recovering well. On day 7 the morning labs show the platelet count has slid from 250 to 110 — no bleeding, no fever, nobody alarmed; "post-op", the team shrugs. By day 9 the count is 70 and the left calf is hot, tense and swollen: a deep vein thrombosis. The drug given to PREVENT clots has caused one. Reaching for a platelet transfusion here would pour fuel on the fire. The lesson is upside-down: the low platelets are not a bleeding problem — they are a clotting alarm, and the answer is a different, stronger blood thinner.

Two diseases share one name: type I vs type II HIT

Not every drop in platelets on heparin is the dangerous one. Type I HIT is a mild, early (within the first 2 days), non-immune nuisance: heparin transiently clumps platelets, the count dips modestly (rarely below 100), and it recovers on its own even if heparin continues. It is benign and needs no action. Type II HIT — the one this article is about — is an immune disaster. It is an antibody-mediated (IgG) reaction that does not merely lower the count; it ACTIVATES platelets throughout the circulation, driving thrombosis. When a clinician says "HIT", they mean type II.

Here is the mechanism, and it explains everything downstream. Heparin binds a small protein released by platelets called platelet factor 4 (PF4). The heparin–PF4 complex looks foreign, and the immune system makes IgG antibodies against it. These antibodies coat the complexes on the platelet surface and cross-link the platelets' Fc receptors — which switches the platelets ON. Activated platelets clump, release still more PF4 (a vicious cycle), and generate thrombin. The count falls because platelets are being consumed into clots, not destroyed uselessly. So the paradox resolves: a LOW platelet count that means HIGH clotting risk.

💡 CLINICAL PEARL

Fix this one sentence in your mind and HIT becomes intuitive: HIT is a PROTHROMBOTIC disorder that happens to lower the platelet count. The thrombocytopenia is a byproduct of platelets being consumed into clots. That is why bleeding is rare and thrombosis — venous AND arterial — is the real threat. Roughly half of untreated patients go on to clot.

The clock: when — and with what — HIT strikes

Timing is the fingerprint. In a patient with no recent heparin, the platelet count typically falls 5 to 10 days after starting the drug — the time the immune system needs to manufacture the IgG. But if the patient was exposed to heparin within the past ~100 days, antibodies may still be circulating, and the count can crash within hours of re-exposure ("rapid-onset HIT"). Risk is not equal across drugs or patients: unfractionated heparin (UFH) carries a substantially higher risk than low-molecular-weight heparin (LMWH), and surgical patients — especially after cardiac or orthopedic surgery — are hit far more often than medical patients.

◆ Clinical example — the "5-to-10-day" rule in action

A medical patient started on UFH for a pulmonary embolism has a stable platelet count for the first four days, then a steady fall beginning on day 6 that reaches half the baseline by day 8 — a textbook immune HIT timeline. Contrast a patient who received heparin during bypass surgery three weeks ago and now, on the first heparin dose of a new admission, drops within two hours: rapid-onset HIT from residual antibodies. Same disease, two clocks.

✅ Key points

Type II HIT is immune (IgG vs PF4/heparin), prothrombotic, and dangerous; type I is benign.
The antibody ACTIVATES platelets → thrombosis (venous and arterial), not bleeding.
Platelets fall 5–10 days after starting heparin; sooner (hours) if recent prior exposure.
Higher risk with UFH than LMWH, and in surgical (cardiac/orthopedic) patients.
The low count reflects platelet CONSUMPTION into clots — a clotting alarm, not a bleeding one.

Recognition: the 4Ts score and confirming the antibody

You cannot test everyone, so you first estimate probability at the bedside. The 4Ts score is the standard pretest tool, each "T" scored 0–2 for a maximum of 8: Thrombocytopenia (how deep the fall — a drop of >50% scores highest), Timing (onset at 5–10 days, or rapid with recent exposure), Thrombosis (a new confirmed clot or skin lesion), and oTher causes of low platelets (are they absent?). A low score (0–3) makes HIT very unlikely and effectively rules it out; intermediate or high scores demand action and testing. Then you confirm in two tiers: an immunoassay for anti-PF4/heparin antibodies (very sensitive — a negative result helps exclude HIT — but not very specific), and, if needed, a functional assay such as the serotonin release assay (SRA) that proves the antibodies actually activate platelets (the confirmatory gold standard).

💡 CLINICAL PEARL

The anti-PF4 immunoassay is sensitive but over-calls: many patients (especially post-cardiac-surgery) form antibodies that never cause disease. So a POSITIVE immunoassay alone does not diagnose HIT — you need the clinical picture (a reasonable 4Ts) and, in unclear cases, a functional assay. Treating a positive antibody in a patient who does not clinically have HIT is a real and harmful trap.

Management: four rules that feel backwards

The moment HIT is seriously suspected — do not wait for confirmatory assays — apply four rules. (1) STOP all heparin immediately: not just the obvious infusion, but every hidden source — subcutaneous prophylaxis, LMWH, heparin line flushes, heparin-bonded catheters. (2) Do NOT give platelet transfusions for the low count: platelets are the very fuel of this disease, and transfusing them can worsen thrombosis. (3) Do NOT start warfarin until the platelet count has recovered (to roughly ≥150): early warfarin drops protein C fast, tipping an already prothrombotic patient into microvascular clotting that can cause venous limb gangrene and skin necrosis. (4) START a non-heparin anticoagulant at once — because stopping heparin alone leaves the patient prothrombotic and still clotting.

◆ Drug example — the replacement anticoagulants

The workhorses are the direct thrombin inhibitors argatroban and bivalirudin — they inhibit thrombin directly, share no structure with heparin, and cannot trigger the PF4 antibody. Argatroban is hepatically cleared (favoured in renal failure); bivalirudin is often used in cardiac settings. Fondaparinux (a synthetic factor-Xa inhibitor) is also widely used. Increasingly, direct oral anticoagulants (DOACs) — especially rivaroxaban — are used, particularly once the patient is stable. Note the pharmacology bridge: heparins live in the Cardiovascular section's anticoagulant chapters, and the coagulation cascade these drugs act on is mapped in this Haemostasis chapter — worth re-reading side by side.

✅ Key points

Use 4Ts to gauge pretest probability; a low score effectively rules HIT out.
Confirm with anti-PF4 immunoassay (sensitive) then a functional assay (SRA, specific) if unclear.
Stop ALL heparin, including LMWH and line flushes — switching to LMWH is not enough.
No platelet transfusions for the count; they can worsen thrombosis.
Start a non-heparin anticoagulant (argatroban, bivalirudin, fondaparinux; DOACs increasingly).
Delay warfarin until platelets recover (≥150) to avoid venous limb gangrene.

⚠️ Common mistakes

Transfusing platelets to "fix" the low count — it adds fuel and can worsen clotting.
Switching heparin to LMWH. LMWH cross-reacts with the same antibody — you must stop ALL heparin.
Starting warfarin early while platelets are still low — risks venous limb gangrene and skin necrosis.
Blaming another cause (sepsis, dilution) and continuing heparin, missing the 5–10 day window.
Treating a positive anti-PF4 antibody alone as HIT, without a compatible clinical picture.

🎓 Questions students ask

If HIT lowers platelets, why is the danger clots rather than bleeding?

Because the antibody ACTIVATES platelets rather than simply destroying them. Activated platelets clump and generate thrombin, forming clots throughout the circulation; the count falls only because platelets are being consumed into those clots. Bleeding is uncommon — the count rarely falls low enough, and the process is fundamentally prothrombotic.

Why can't I just switch from unfractionated heparin to LMWH?

The HIT antibody targets the PF4/heparin complex, and LMWH forms enough of that complex to cross-react. Switching to LMWH keeps feeding the same immune reaction. HIT requires stopping ALL heparin exposure and moving to a structurally unrelated anticoagulant such as a direct thrombin inhibitor or fondaparinux.

Why is early warfarin dangerous in HIT?

Warfarin rapidly lowers protein C (a natural anticoagulant) before it lowers the clotting factors, creating a transient hypercoagulable state. In a patient already thrombotic from HIT, that tip can trigger microvascular clotting — venous limb gangrene and skin necrosis. Wait until platelets recover to ≥150, overlap with a non-heparin anticoagulant, and use only modest starting doses.

Once someone has had HIT, can they ever receive heparin again?

In general, no — the label of HIT means future heparin is avoided. The antibodies usually wane over weeks to months, and in rare, carefully chosen situations (such as cardiac surgery when antibodies have cleared and the assay is negative) a brief heparin re-exposure may be considered by specialists. For routine care, treat prior HIT as a firm reason to use a non-heparin anticoagulant.

Test yourself

On day 8 of unfractionated heparin, a post-op patient's platelet count has fallen from 260 to 95 and a new DVT appears. What is the single most important immediate step?

🫁 In one breath

HIT (type II) is an immune, IgG-vs-PF4/heparin reaction that ACTIVATES platelets — low count, HIGH clot risk.
Platelets fall 5–10 days after heparin (hours if prior exposure); worse with UFH and after surgery.
Score with 4Ts, confirm with anti-PF4 immunoassay then a functional assay (SRA).
Stop ALL heparin; no platelet transfusions; no early warfarin; start a direct thrombin inhibitor or fondaparinux (DOACs increasingly).

📚 Sources

Katzung BG. Basic & Clinical Pharmacology — Drugs used in coagulation disorders: heparin, LMWH & direct thrombin inhibitors; heparin-induced thrombocytopenia.
American Society of Hematology (ASH) 2018 Guidelines for Management of Venous Thromboembolism: Heparin-Induced Thrombocytopenia.
Cuker A, et al. The 4Ts score for the diagnosis of heparin-induced thrombocytopenia — validation and clinical use.
Brunton LL, et al. Goodman & Gilman's The Pharmacological Basis of Therapeutics — Anticoagulants; HIT and non-heparin anticoagulants.
Arepally GM. Heparin-induced thrombocytopenia. Blood (review of pathophysiology and PF4 antibody biology).

More in Haemostasis & Anticoagulation →